Teriparatide
Parathyroid hormone (1–34) analog
A parathyroid hormone fragment studied in osteoporosis research, with trials examining fractures and bone mineral density.
Also referenced as: PTH (1-34)
Overview
The 2001 fracture-prevention trial studied parathyroid hormone (1–34) in postmenopausal women with osteoporosis. It measured new fractures and bone mineral density, making it a foundational clinical comparator for bone-active peptide research.
At a glance
Mechanism of action
Teriparatide represents the biologically active 1–34 fragment of parathyroid hormone and is studied in bone-remodeling contexts.
Mechanistic description reflects published research-literature understanding. Much peptide research is preclinical (in-vitro or animal-model); mechanism in humans may differ and is not established for many compounds.
What it's studied for
Research contexts in which Teriparatide appears in the literature. Listing a research area is not a claim of efficacy or a therapeutic indication.
Key characteristics
- The cited trial concerns a defined osteoporosis population. It does not establish generalized recovery or performance benefits, or equivalence with research-supplier material.
How it compares
The cited trial concerns a defined osteoporosis population. It does not establish generalized recovery or performance benefits, or equivalence with research-supplier material.
Commonly studied alongside
Compounds frequently researched together with Teriparatide in the literature. Cross-referenced for research context — not a usage or combination recommendation.
Compare and calculate
Side-by-side pages for the pairings the literature already documents for Teriparatide, plus the unit-conversion reference for a reconstituted vial. Factual comparisons of documented characteristics — not a recommendation to combine or use any compound.
Handling & Stability
Lyophilized peptides are stored cold, protected from light, and reconstituted only at the time of intended in-vitro work.
- Avoid repeated freeze-thaw cycles
- Verify supplier lot and Certificate of Analysis
- Follow institutional lab-safety protocols
Analytical & COA Concepts
Reputable research suppliers publish a third-party Certificate of Analysis per batch. Key analytical concepts referenced in COAs include:
Category Context
Teriparatide sits in the Specialty & Research area of the PeptiDex library.
- Entry type: Research compound reference
- Specialty & Research category hub →
- Browse the full library →
- Glossary of terms →
Research reference
No supplier listing is attached to this profile. The cited study describes its own formulation and population.
Read the evidence guide →Frequently asked questions
What is the evidence context for Teriparatide?
The cited trial concerns a defined osteoporosis population. It does not establish generalized recovery or performance benefits, or equivalence with research-supplier material.
Does this reference establish that a supplier product is equivalent?
No. A study of a defined pharmaceutical formulation does not verify the identity, purity, sterility or clinical suitability of any separately sold material.
Answers are educational summaries of research-literature context and do not constitute medical advice. See the Research Library, COA guide, and Storage & Handling guide for more.
References
Publications indexed in PubMed and linked to this profile, including original studies and reviews. Publication labels reflect PubMed indexing, not evidence strength. Listing a study records that it exists and is indexed — it is not a claim of efficacy, a therapeutic indication, or an endorsement of its conclusions. Much of this literature is preclinical (in-vitro or animal-model).
- Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis
Randomized controlled trial · Citation and indexing details
Bibliographic metadata refreshed from PubMed on 2026-09-20. This checks the record identity and metadata; it is not a new review of every scientific claim. A reference may concern a related molecule or formulation: read its methods and the context above. See the editorial policy.